UCB stock
UCB.BRBRUUCB S.A., HealthcareISIN BE0003739530
78Score 78 out of 100, Strong
Price and trend
71 / 100
Price history
+29% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 21% above it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 70).
The price is 1.2% below its 52-week high. Largest decline in 20 years: 62% (June 2007 to October 2008).
Chart figures for advanced users
- SMA 50$256.84
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$270.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$220.20
- The lowest closing price of the last twelve months.
- Resistance$332.47
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- UCB S.A. belongs to the Biotechnology industry (Belgium) and, with a market value of $62.63B, is number 4 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $8.61B (up 25.8% year on year) and earnings of $1.73B (up 46.3%).
- For fiscal 2026, analysts expect on average revenue of $9.95B (up 15.5%) and adjusted earnings per share of $14.13 (up 26.6%).
Show more
- MEQIRI Score 78 out of 100 (Strong): rank 35 of 714 in Healthcare, median 53.
- The P/E is 25.6 (Biotechnology median 21.3, own median of recent years 21.5).
- Our model puts fair value at $358.12, with the price 9% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 26 years.Capital allocation 71
- High marginNet margin 25.7% over the last 12 months, Biotechnology median −93.3%.Profitability 88
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $275.48 and expensive above $511.61 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $442.69 (cash-flow model) and $273.55 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9%. At 10% the fair value would be $325.17, at 8% it would be $403.58.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 24.5% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating 15%, net 20%. Last 12 months: net 26%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 30 Jul 2026EPS reported $7.53 (expected $5.60)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 9.5% since 15 Oct 2026.
- Earnings per share
- $14.13+9.5%
- Revenue
- $9.95B+3.0%
- Earnings per share
- $16.36+7.5%
- Revenue
- $11.04B+3.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −11.2%2026 guidance upgraded versus the earlier guidance, after strong growth in the first half.
“So definitely a strong growth at the beginning of the year, built upon the portfolio of the growth driver that we have, which allow us to move on the right-hand side of the slide when you can see, and Sandrine will comment on that, that we have upgraded our guidance for 2026 versus what we had shared with you earlier.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at UCB
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vertex PharmaceuticalsVRTX $138.69B76
- ModernaMRNA $100.63B48
- Regeneron PharmaceuticalsREGN $99.23B81
- argenxARGX $61.25B70
- Lonza GroupLONN.SW $55.85B63
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
ETFs that hold UCB
Held by 130 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI EMU Socially Responsible UCITS ETF A DistributionUIMR | 2.26% | 0.20% | €1.22B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 1.99% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 1.98% | 0.18% | €954.9M |
Show 5 more
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 1.98% | 0.18% | €653.55M |
| Amundi MSCI EMU SRI Climate Paris Aligned UCITS ETF DR (C)SRHE | 1.92% | 0.18% | €119.46M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 1.92% | 0.46% | €729.65M |
| Amundi S&P Eurozone Climate Paris Aligned UCITS ETF AccZPAB | 1.47% | 0.20% | €3.34B |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.26% | 0.40% | €1.49B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.